<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02799355</url>
  </required_header>
  <id_info>
    <org_study_id>GCNI-CHC</org_study_id>
    <nct_id>NCT02799355</nct_id>
  </id_info>
  <brief_title>Treatment of Chronic Hepatitis With Sofosbuvir in Combination With Ribavirin With or Without Pegylated Interferon: North India Gastroenterology Consortium</brief_title>
  <acronym>GCNI-CHC</acronym>
  <official_title>Treatment of Chronic Hepatitis With Sofosbuvir in Combination With Ribavirin With or Without Pegylated Interferon: North India Gastroenterology Consortium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dayanand Medical College and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dayanand Medical College and Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Of the six main genotypes of the hepatitis C virus (HCV), genotypes 2 and 3 account for
      approximately 30% of chronic infections worldwide. In North India, Genotypes 3 and 1 account
      for 95% of chronic hepatitis C patients The first three direct-acting antiviral agents to
      receive FDA approval—boceprevir, telaprevir, and simeprevir—do not currently have a role in
      the treatment of genotype 3 infection. In contrast, the direct-acting antiviral agents,
      daclatasvir and sofosbuvir, have good activity against all genotypes. The SVR rates of 90 -
      100% in genotype 3 were achieved with oral sofosbuvir plus ribavirin regimen to 24 weeks.
      Similar SVR rates were achieved in Genotype 1 with oral sofosbuvir plus weight based
      ribavirin and Pegylated Interferon alpha 2 a. However, the ongoing discovery and development
      of agents that directly target various stages of HCV replication are likely to provide
      HCV-infected patients with effective interferon-free therapy. HCV genotype 3 infection is
      associated with a higher incidence of hepatic steatosis, more rapid progression of fibrosis,
      and possibly a greater risk of hepatocellular carcinoma than is HCV genotype 2
      infection.Moreover, patients with HCV genotype 3 infection are less responsive to
      peginterferon based treatment than are patients with HCV genotype 2 infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sofosbuvir is an oral nucleotide analogue inhibitor of the HCV NS5B polymerase that is
      effective against HCV genotypes 2 and 3 when it is administered in combination with weight
      based ribavirin for 24 weeks. In Genotype 1, a combination of Pegylated Interferon alpha 2 a
      with oral Sofosbuvir and weight based Ribavirin for 12 weeks resulted in 90 -100 % sustained
      virological response rates (SVR). These SVR rates for chronic hepatitis C genotypes 1,2 and 3
      are all based on Western studies. The investigators plan to conduct a retrospective study in
      Northern India region on patients treated with Sofosbuvir and Ribavirin or Sofosbuvir,
      Ribavirin and Peginterferon alpha 2a. The purpose of the investigators study is to assess the
      percentage of patients with sustained virologic response.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with sustained virologic response at 12 weeks after the end of treatment.</measure>
    <time_frame>3 month</time_frame>
    <description>Sustained virologic response was defined as a level of HCV RNA below the lower limit of quantification (25 IU per milliliter)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effect</measure>
    <time_frame>3 month</time_frame>
    <description>Assess the treatment side effect</description>
  </secondary_outcome>
  <enrollment type="Actual">1203</enrollment>
  <condition>Hepatitis, Chronic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir, Ribavirin, With or Without Pegylated Interferon</intervention_name>
    <description>Retrospective will carried out to find percentage of patients with sustained virologic response at 12 weeks after the end of treatment</description>
    <other_name>Sofosbuvir in Combination With Ribavirin With or Without Pegylated Interferon</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study is a retrospective study conducted on 1500 to 2000 patients who have recieved
        treatment of Sofosbuvir and Ribavirin or Sofosbuvir, Ribavirin and peg interferon alpha 2a
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age more then 18 years.

          -  Patient who on treatment of either Sofosbuvir and Ribavirin (24 weeks) or Sofosbuvir,
             Ribavirin and peginterferon (12 weeks).

        Exclusion Criteria:

          -  Patient who are lost to follow up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Gastroenterology, D.M.C. and Hospital</name>
      <address>
        <city>Ludhiana</city>
        <state>Punjab</state>
        <zip>141001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <results_reference>
    <citation>Tapper EB, Afdhal NH. Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3. J Viral Hepat. 2013 Oct;20(10):669-77. doi: 10.1111/jvh.12168. Review.</citation>
    <PMID>24010641</PMID>
  </results_reference>
  <results_reference>
    <citation>Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009 Apr;49(4):1335-74. doi: 10.1002/hep.22759.</citation>
    <PMID>19330875</PMID>
  </results_reference>
  <results_reference>
    <citation>European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011 Aug;55(2):245-64. doi: 10.1016/j.jhep.2011.02.023. Epub 2011 Mar 1.</citation>
    <PMID>21371579</PMID>
  </results_reference>
  <results_reference>
    <citation>Goossens N, Negro F. Is genotype 3 of the hepatitis C virus the new villain? Hepatology. 2014 Jun;59(6):2403-12. doi: 10.1002/hep.26905. Epub 2014 Apr 14. Review.</citation>
    <PMID>24155107</PMID>
  </results_reference>
  <results_reference>
    <citation>Wartelle-Bladou C, Le Folgoc G, Bourlière M, Lecomte L. Hepatitis C therapy in non-genotype 1 patients: the near future. J Viral Hepat. 2012 Aug;19(8):525-36. doi: 10.1111/j.1365-2893.2012.01634.x. Review.</citation>
    <PMID>22762136</PMID>
  </results_reference>
  <results_reference>
    <citation>Marcellin P, Cheinquer H, Curescu M, Dusheiko GM, Ferenci P, Horban A, Jensen D, Lengyel G, Mangia A, Ouzan D, Puoti M, Rodriguez-Torres M, Shiffman ML, Schmitz M, Tatsch F, Rizzetto M. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology. 2012 Dec;56(6):2039-50. doi: 10.1002/hep.25892. Epub 2012 Aug 8.</citation>
    <PMID>22706730</PMID>
  </results_reference>
  <results_reference>
    <citation>Alberti A. Optimizing PEG-interferon and ribavirin combination therapy for patients infected with HCV-2 or HCV-3: is the puzzle completed? J Hepatol. 2004 Jun;40(6):1032-5. Review.</citation>
    <PMID>15158348</PMID>
  </results_reference>
  <results_reference>
    <citation>Manns MP, von Hahn T. Novel therapies for hepatitis C - one pill fits all? Nat Rev Drug Discov. 2013 Aug;12(8):595-610. doi: 10.1038/nrd4050. Epub 2013 Jun 28. Review.</citation>
    <PMID>23807378</PMID>
  </results_reference>
  <results_reference>
    <citation>Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013 May 16;368(20):1878-87. doi: 10.1056/NEJMoa1214853. Epub 2013 Apr 23.</citation>
    <PMID>23607594</PMID>
  </results_reference>
  <results_reference>
    <citation>Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Weiland O, Reesink HW, Ferenci P, Hézode C, Esteban R; VALENCE Investigators. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014 May 22;370(21):1993-2001. doi: 10.1056/NEJMoa1316145. Epub 2014 May 4.</citation>
    <PMID>24795201</PMID>
  </results_reference>
  <results_reference>
    <citation>Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, Hindes RG, Berrey MM. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013 Jan 3;368(1):34-44. doi: 10.1056/NEJMoa1208953.</citation>
    <PMID>23281974</PMID>
  </results_reference>
  <results_reference>
    <citation>Chakravarti A, Dogra G, Verma V, Srivastava AP. Distribution pattern of HCV genotypes &amp; its association with viral load. Indian J Med Res. 2011 Mar;133:326-31.</citation>
    <PMID>21441689</PMID>
  </results_reference>
  <results_reference>
    <citation>Singh S, Malhotra V, Sarin SK. Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C infection in India. Indian J Med Res. 2004 Apr;119(4):145-8.</citation>
    <PMID>15147119</PMID>
  </results_reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2016</study_first_submitted>
  <study_first_submitted_qc>June 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2016</study_first_posted>
  <last_update_submitted>September 24, 2016</last_update_submitted>
  <last_update_submitted_qc>September 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dayanand Medical College and Hospital</investigator_affiliation>
    <investigator_full_name>Prof. Sandeep S Sidhu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

